Management of Hematologic Disorders

  • Author: David Aboulafia, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 4/1/16 (What's New)

Summary

  • Therapy is not always necessary because 1% to 20% of patients may experience spontaneous remission, and the incidence of significant bleeding is low despite low platelet counts[Walsh 1985; Brusamolino 1989]
  • In absence of HIV infection, rituximab associated with complete remission in 98% of relapsed/refractory ITP cases and longer median PFS vs conventional therapy[Tun 2012]; limited data on rituximab use for HIV-associated ITP
  • Antiretroviral Therapy
    • Standard of care for patients with HIV-associated thrombocytopenia is ART initiation
    Corticosteroids and Immunoglobulin Therapy
      Anti-Rh Antibody
        Splenectomy
          Alternative Therapies

          Action required